Association between in vivo iododeoxyuridine labeling, MIB-1 expression, malignancy grade and clinical stage in human prostate cancer

被引:8
作者
Borre, M
Hoyer, M
Sorensen, FB
Nerstrom, B
Overgaard, J
机构
[1] Aarhus Univ Hosp, Danish Canc Soc, Dept Expt Clin Oncol, DK-8000 Aarhus, Denmark
[2] Aarhus Univ Hosp, Danish Canc Soc, Dept Urol, DK-8000 Aarhus, Denmark
[3] Aarhus Univ Hosp, Danish Canc Soc, Dept Oncol, DK-8000 Aarhus, Denmark
[4] Aarhus Univ Hosp, Danish Canc Soc, Dept Pathol, DK-8000 Aarhus, Denmark
关键词
prostate cancer; proliferation; prognostic markers; Ki-67;
D O I
10.1111/j.1699-0463.1998.tb01362.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Large variability in the biological behavior of prostate cancer makes prognostic markers important. The extent of tumor cell proliferation has been suggested as an important predictor of clinical outcome. Fifty-five patients suspected of having or with previously diagnosed prostate cancer were labeled in vivo with IdUrd (a thymidine analogue incorporated into DNA in S-phase cells) by intravenous infusion before transurethral resection. IdUrd-labeled cells and MIB-1-positive cells were detected by immunohistochemistry. We found statistically significant associations between the tumor cell proliferation rates measured by in vivo IdUrd labeling and MIB-1 expression in formalin-fixed paraffin-embedded tumors. Good correlations were also found between S-phase fraction, MIB-1 expression, clinical stage and malignancy grade. These results make larger retrospective studies on archival tissue meaningful.
引用
收藏
页码:389 / 395
页数:7
相关论文
共 28 条
  • [1] [Anonymous], 1980, Histological typing of prostate tumours / F. K. Mostofi, in collaboration with I. Sesterhenn
  • [2] LONG-TERM SURVIVAL AND MORTALITY IN PROSTATE-CANCER TREATED WITH NONCURATIVE INTENT
    AUS, G
    HUGOSSON, J
    NORLEN, L
    [J]. JOURNAL OF UROLOGY, 1995, 154 (02) : 460 - 465
  • [3] Berges RR, 1995, CLIN CANCER RES, V1, P473
  • [4] Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy
    Bettencourt, MC
    Bauer, JJ
    Sesterhenn, IA
    Mostofi, FK
    McLeod, DG
    Moul, JW
    [J]. JOURNAL OF UROLOGY, 1996, 156 (03) : 1064 - 1068
  • [5] Borre M, 1997, CANCER, V80, P917
  • [6] Brown RW, 1996, CLIN CANCER RES, V2, P585
  • [7] BYAR DP, 1972, CANCER-AM CANCER SOC, V30, P5, DOI 10.1002/1097-0142(197207)30:1<5::AID-CNCR2820300103>3.0.CO
  • [8] 2-S
  • [9] CELL-PROLIFERATION IN PROSTATIC ADENOCARCINOMA - INVITRO MEASUREMENT BY 5-BROMODEOXYURIDINE INCORPORATION AND PROLIFERATING CELL NUCLEAR ANTIGEN EXPRESSION
    CARROLL, PR
    WALDMAN, FM
    ROSENAU, W
    COHEN, MB
    VAPNEK, JM
    FONG, P
    NARAYAN, P
    MAYALL, BH
    [J]. JOURNAL OF UROLOGY, 1993, 149 (02) : 403 - 407
  • [10] MONOCLONAL-ANTIBODIES AGAINST RECOMBINANT PARTS OF THE KI-67 ANTIGEN (MIB-1 AND MIB-3) DETECT PROLIFERATING CELLS IN MICROWAVE-PROCESSED FORMALIN-FIXED PARAFFIN SECTIONS
    CATTORETTI, G
    BECKER, MHG
    KEY, G
    DUCHROW, M
    SCHLUTER, C
    GALLE, J
    GERDES, J
    [J]. JOURNAL OF PATHOLOGY, 1992, 168 (04) : 357 - 363